U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07549464) titled 'Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia' on April 20.
Brief Summary: The goal of this clinical research study is to find the highest tolerable dose of PLM-102 that can be given to patients who have AML/MDS that is refractory and/or relapsed. The safety of PLM-102 will also be studied.
Study Start Date: Oct. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Acute Myeloid Leukemia
Intervention:
DRUG: PLM-102
Given by mouth
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. Anderson Cancer Center
Disclaimer: Curated by HT Syndication....